AccelerateEU : Yves Jongen

🔬 𝗔𝘀𝘁𝗮𝘁𝗶𝗻𝗲-𝟮𝟭𝟭: 𝗔 𝗚𝗮𝗺𝗲 𝗖𝗵𝗮𝗻𝗴𝗲𝗿 𝗶𝗻 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀

"It's extraordinary what's happening, and astatine is going to play a role."
— Yves Jongen, 𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗮𝗻𝗱 𝗖𝗵𝗶𝗲𝗳 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗢𝗳𝗳𝗶𝗰𝗲𝗿 𝗮𝘁 𝗜𝗕𝗔

Astatine-211 is emerging as a key player in the future of theranostics, but what does it take to bring this promising isotope to clinical use?

In this exclusive video, Yves Jongen shares his insights on:
✅ The exciting trends shaping the theranostic market
✅ The technical challenges in developing astatine production infrastructure
✅ How logistics must evolve to ensure global access

Watch now to explore the future of astatine-based therapies! 🎥👇 AccelerateEU Institut Jules Bordet , IBA RadioPharma Solutions
Institut de Cancérologie de l'Ouest (ICO), Erasmus MC, Arronax, Forschungszentrum Jülich, Rigshospitalet, Københavns Universitet - University of Copenhagen, INSERM, SCK CEN, Campus da Universidade de Coimbra na Figueira da Foz, TetraKit Technologies, Oncidium foundation, LabLogic Group, Vicomtech, Université libre de Bruxelles, National Centre for Nuclear Research